Medicare weight-loss drug coverage could overwhelm doctors
Summary
Starting July 1, Medicare will offer weight-loss drugs like Wegovy and Zepbound for $50 a month, making them more affordable for many seniors. This program may cause a high demand for these drugs, which could overwhelm doctors and clinics due to extra paperwork and patient counseling needs.Key Facts
- Medicare has not covered weight-loss drugs until now due to legal restrictions.
- The new program results from a deal President Donald Trump made with drug companies Eli Lilly and Novo Nordisk to lower prices.
- About 14 million Medicare beneficiaries are overweight or obese and may seek these drugs.
- Patients must go through a “prior authorization” process to prove they qualify for the drugs.
- Doctors worry this process and patient counseling may overload clinics and cause delays.
- The program runs only until the end of 2027 and does not cover nutrition or behavioral support services.
- The $50 monthly cost may still be too expensive for some seniors on fixed incomes.
- Some seniors who already have these drugs prescribed for other reasons under Part D won’t qualify for the Medicare discount.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.